# Verona Pharma plc (VRNA) Source: https://www.quantisnow.com/company/VRNA Generated: 2026-11-11T08:03:16.139Z - Ticker: VRNA - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Pharmaceutical Preparations - IPO year: 2017 - Website: veronapharma.com ## About Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 2 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. It also focuses on developing ensifentrine for the treatment of COVID-19. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom. ## Latest VRNA news and filings - 2025-11-17 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-verona-pharma-plc-6281850) - 2025-11-14 21:27 UTC [SEC Form SCHEDULE 13G filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-verona-pharma-plc-6280823) - 2025-11-14 21:00 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-verona-pharma-plc-6280178) - 2025-11-14 15:24 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Verona Pharma plc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-verona-pharma-plc-6279519) - 2025-10-17 15:30 UTC [SEC Form 15-12G filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-verona-pharma-plc-6236689) - 2025-10-08 20:45 UTC [SEC Form 4] [General Counsel Fisher Andrew returned 1,349,887 units of Ordinary Shares to the company and converted options into 931,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/general-counsel-fisher-andrew-returned-1349887-units-of-ordinary-shares-6227819) - 2025-10-08 20:44 UTC [SEC Form 4] [President and CEO Zaccardelli David returned 15,461,424 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-zaccardelli-david-returned-15461424-units-of-ordinary-6227816) - 2025-10-08 20:43 UTC [SEC Form 4] [Chief Medical Officer Rickard Kathleen A. returned 3,564,852 units of Ordinary Shares to the company and converted options into 1,131,984 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-rickard-kathleen-a-returned-3564852-units-of-6227812) - 2025-10-08 20:42 UTC [SEC Form 4] [Chief Financial Officer Hahn Mark W returned 14,550,248 units of Ordinary Shares to the company and converted options into 3,285,280 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-hahn-mark-w-returned-14550248-units-of-6227809) - 2025-10-08 20:41 UTC [SEC Form 4] [Director Austwick Michael returned 84,712 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-austwick-michael-returned-84712-units-of-ordinary-shares-to-6227807) - 2025-10-08 20:40 UTC [SEC Form 4] [Director Ullman Anders returned 430,856 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ullman-anders-returned-430856-units-of-ordinary-shares-to-6227802) - 2025-10-08 20:38 UTC [SEC Form 4] [Director Shah Mahendra returned 165,472 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-shah-mahendra-returned-165472-units-of-ordinary-shares-to-6227797) - 2025-10-08 20:36 UTC [SEC Form 4] [Director Sinha Vikas returned 166,112 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-sinha-vikas-returned-166112-units-of-ordinary-shares-to-6227787) - 2025-10-08 20:35 UTC [SEC Form 4] [Director Deschamps Lisa returned 156,856 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-deschamps-lisa-returned-156856-units-of-ordinary-shares-to-6227784) - 2025-10-08 20:34 UTC [SEC Form 4] [Director Ebsworth David R returned 1,570,099 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ebsworth-david-r-returned-1570099-units-of-ordinary-shares-6227780) - 2025-10-08 20:33 UTC [SEC Form 4] [Director Edwards Martin returned 229,992 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-edwards-martin-returned-229992-units-of-ordinary-shares-to-6227775) - 2025-10-08 20:32 UTC [SEC Form 4] [Director Brady James Aloysius returned 95,176 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-brady-james-aloysius-returned-95176-units-of-ordinary-shares-6227773) - 2025-10-08 20:31 UTC [SEC Form 4] [Director Cunningham Kenneth returned 151,776 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-cunningham-kenneth-returned-151776-units-of-ordinary-shares-to-6227768) - 2025-10-08 20:30 UTC [SEC Form 4] [Director Ackermann Christina returned 136,072 units of Ordinary Shares to the company and converted options into 72,000 units of Ordinary Shares, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-ackermann-christina-returned-136072-units-of-ordinary-shares-to-6227752) - 2025-10-07 17:03 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verona-pharma-plc-6226022) - 2025-10-07 17:01 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verona-pharma-plc-6226021) - 2025-10-07 17:00 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verona-pharma-plc-6226020) - 2025-10-07 16:59 UTC [SEC Form POSASR filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-verona-pharma-plc-6226018) - 2025-10-07 16:57 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verona-pharma-plc-6226017) - 2025-10-07 16:56 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verona-pharma-plc-6226016) - 2025-10-07 16:55 UTC [SEC Form POS AM filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-verona-pharma-plc-6226015) - 2025-10-07 16:54 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verona-pharma-plc-6226013) - 2025-10-07 16:52 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-verona-pharma-plc-6226012) - 2025-10-07 12:56 UTC [SEC Form 25-NSE filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-verona-pharma-plc-6225686) - 2025-10-07 11:03 UTC [SEC Form 8-K] [Verona Pharma plc filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/verona-pharma-plc-filed-sec-form-8-k-completion-of-acquisition-6225415) - 2025-10-07 10:45 UTC [Merck Completes Acquisition of Verona Pharma](https://www.quantisnow.com/insight/merck-completes-acquisition-of-verona-pharma-6225358) - 2025-10-06 20:05 UTC [Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales](https://www.quantisnow.com/insight/acquisition-of-verona-by-msd-approved-by-the-high-court-6224551) - 2025-09-24 20:20 UTC [SEC Form 8-K] [Verona Pharma plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/verona-pharma-plc-filed-sec-form-8-k-submission-of-matters-6210656) - 2025-09-24 20:05 UTC [Shareholders of Verona Pharma Approve Proposed Acquisition by Merck](https://www.quantisnow.com/insight/shareholders-of-verona-pharma-approve-proposed-acquisition-by-merck-6210508) - 2025-09-16 10:00 UTC [Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025](https://www.quantisnow.com/insight/verona-pharma-to-present-additional-analyses-of-the-phase-3-6201570) - 2025-09-10 21:00 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-verona-pharma-plc-6196837) - 2025-09-09 20:05 UTC [SEC Form 8-K] [Verona Pharma plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/verona-pharma-plc-filed-sec-form-8-k-leadership-update-financial-6194980) - 2025-09-09 20:05 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Verona Pharma plc](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-verona-pharma-plc-6194972) - 2025-09-03 20:32 UTC [SEC Form 4] [President and CEO Zaccardelli David gifted 1,200,000 units of Ordinary Shares, decreasing direct ownership by 9% to 12,176,144 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-zaccardelli-david-gifted-1200000-units-of-ordinary-6188253) - 2025-09-03 20:30 UTC [SEC Form 4] [Chief Medical Officer Rickard Kathleen A. gifted 189,600 units of Ordinary Shares, decreasing direct ownership by 7% to 2,417,872 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-rickard-kathleen-a-gifted-189600-units-of-6188221) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VRNA - Earnings history: https://www.quantisnow.com/earnings/VRNA - Dividend history: https://www.quantisnow.com/dividends/VRNA - Insider transactions: https://www.quantisnow.com/insiders/VRNA - Options chain: https://www.quantisnow.com/options/VRNA - SEC 8-K filings only: https://www.quantisnow.com/company/VRNA/8-k - RSS and alerts for VRNA: https://www.quantisnow.com/docs/rss-feeds.md